Elgin, Ill, November 6, 2025 - The Middleby Corporation (NASDAQ: MIDD), a leading worldwide manufacturer of equipment for the commercial foodservice, food processing, and residential kitchen industries, today reported net earnings for the third quarter of 2025. Tim FitzGerald, CEO of The Middleby Corporation said, "As part of our efforts to maximize shareholder value, we are conducting a strategic review of our Residential Kitchen business unit and determined that a non-cash impairment charge was necessary ...

COLUMBIA, SC., November 6, 2025 / United Homes Group, Inc. (the "Company") (NASDAQ: UHG) today announced results for the three and nine months ended September 30, 2025. Third Quarter 2025 Operating Results For the third quarter 2025, net loss was $31.3 million, or $0.53 per diluted share, which included a loss from the change in fair value of derivative liabilities of $27.2 million, with that change predominantly due to changes in fair value on potential earn-out consideration and warrants due to fluctuatio ...

Third Quarter 2025 Highlights COLUMBIA, SC., November 6, 2025 / United Homes Group, Inc. (the "Company") (NASDAQ: UHG) today announced results for the three and nine months ended September 30, 2025. Exhibit 99.1 UNITED HOMES GROUP, INC. REPORTS 2025 THIRD QUARTER RESULTS Third Quarter 2025 Operating Results For the third quarter 2025, net loss was $31.3 million, or $0.53 per diluted share, which included a loss from the change in fair value of derivative liabilities of $27.2 million, with that change predom ...

Exhibit 99.1 Tripadvisor Reports Third Quarter 2025 Financial Results and Aligns Operating Model with Experiences-Led Strategy Viator and Brand Tripadvisor to organize in support of Group priorities in experiences New structure to leverage Group data to capitalize on AI-enabled opportunities Optimizing Brand Tripadvisor portfolio to maximize ef iciencies NEEDHAM, MA, November 6, 2025 — Tripadvisor, Inc. (NASDAQ: TRIP) today announced financial results for the third quarter ended September 30, 2025, and a re ...

Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti- TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI- 052 - Pipeline: Oral Inhibitors: ITK Franchise ● Announced Anticipated Phase 2 Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3, in an Additional Indication: Aclaris expects to fur ...

Exhibit 99.1 BK Technologies Reports Third Quarter 2025 Revenue Increase of 21% to $24.4 Million; Net Income Increases 46% to $3.4 Million WEST MELBOURNE, FL November 6, 2025 / BK Technologies Corporation (NYSE American: BKTI) (the "Company," "BK Technologies"), a provider of advanced public safety communications solutions, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. The Company will host a conference call today, November 6, 2025, at 9:00 a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File No. 001-35962 NATHAN'S FAMOUS, INC. (Exact name of registrant as specified in its charter) Delaware 11-3166443 (State or other jurisdiction of incorporation or organization) One Jericho Plaza, Jericho, New York 11753 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: 516-338-8500 Securities registered pursuant to Section 12(b) of the Act: | | | Nam ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | England and Wales | N ...

NEWS RELEASE Exhibit 99.1 Earnings Guidance The Company narrows its 2025 adjusted EPS (non-GAAP) guidance range of $3.92 to $4.02 from its original 2025 adjusted EPS (non-GAAP) guidance range of $3.92 to $4.12. Additionally, the Company reaffirms its long-term adjusted EPS (non-GAAP) annual growth target of 4% to 6% through 2029 based on the 2025 adjusted EPS (non-GAAP) guidance midpoint of $4.02. The Company expects adjusted EPS growth in the upper half of the 4% to 6% range beginning in 2026. Adjusted EPS ...

Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2025 Financial Results HOLLISTON, Mass., November 6, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2025. "Our third-quarter performance highlights our growth opportunity while we advance efforts to fortify our capital structure. We saw another uptick in our performance on a sequential basis as our focus on executing, accelerati ...